Citius Pharmaceuticals, Inc. current report, 06 October 2020

Full document

Citius Pharmaceuticals, Inc. - Form 8-K Summary

Business Context and Reporting Period

Date of Report: October 6, 2020
Company: Citius Pharmaceuticals, Inc. (Nasdaq: CTXR)
Event: Entry into a Material Definitive Agreement (Item 1.01).
Context: Citius, through its newly established subsidiary NoveCite, Inc., entered into an exclusive, worldwide license agreement with Novellus Therapeutics Limited. The agreement covers the development and commercialization of a stem cell therapy for acute pneumonitis using patented mesenchymal stem cell (MSC) technology.

Key Financial Metrics and Transaction Terms

This filing details a strategic transaction rather than periodic financial performance. Key financial terms include:

  • Upfront Payment: $5,000,000 paid upon execution.
  • Equity Issuance: NoveCite issued shares representing 25% of its outstanding equity to Novellus; Citius retains 75%.
  • Milestone Payments: Up to $51,000,000 payable upon achieving regulatory and developmental milestones.
  • Royalties: Low double-digit percentages of net sales, potentially reducing to upper-single digits upon patent expiration.
  • Sublicense Fees: NoveCite will remit a mid-twenties percentage of any sublicensee fees received to Novellus.
  • Revenue Share: NoveCite is entitled to 50% of any revenue Novellus receives from transactions involving the original cell line.

Note: The filing does not provide specific revenue, profit, cash flow, or debt figures for Citius Pharmaceuticals, Inc. for the reporting period.

Material Changes and Obligations

The primary material change is the formation of NoveCite, Inc., and the acquisition of the exclusive license. Key obligations include:

  • Commercialization Targets: NoveCite must use commercially reasonable efforts to make at least one product available in the U.S. and one other major market (UK, France, Germany, China, or Japan).
  • Regulatory Milestones:
    • File an Investigational New Drug (IND) application within 5 years.
    • Receive regulatory approval in the U.S. or a major market within 10 years.
  • Right of First Negotiation: NoveCite has the right to negotiate exclusively for new products developed by Novellus in the acute pneumonitis field.

Outlook, Risks, and Contingencies

Outlook: The agreement positions the company to develop a therapy for acute pneumonitis, a condition where inflammation is a major agent. The term continues until the expiration of the last-to-expire royalty term unless terminated earlier.

Risks and Termination:

  • Either party may terminate for material default or bankruptcy.
  • Novellus may terminate if NoveCite challenges the validity of licensed patents.
  • NoveCite may terminate without cause upon 90 days' written notice.
  • Novellus is prohibited from commercializing competing MSC products for acute pneumonitis during the term.

Investor Verification Checklist

  • Verify the financial impact of the $5 million upfront payment on Citius's current cash position.
  • Confirm the capitalization structure of the new subsidiary, NoveCite, Inc.
  • Review the full license agreement (to be filed as an exhibit to the 10-K) for specific definitions of "milestones" and "net sales."
  • Assess the timeline for the required IND filing (within 5 years) and regulatory approval (within 10 years).
  • Monitor the press release (Exhibit 99.1) for additional market commentary.